Search results for "COMB"

showing 10 items of 7115 documents

New approaches in the treatment of Adamantiades-Behçet's disease.

2005

Purpose of review To update clinicians on the recent advances in the treatment of Adamantiades-Behcet's disease. Recent findings Interferon-α-2a and infliximab have proved able to induce prompt remission in the vast majority of Adamantiades-Behcet's patients with DMARD-resistant uveoretinitis. Efficacy of interferon-α-2a has also been reported for mucocutaneous lesions, arthritis, and (more anecdotally) for neuro-Behcet, while results from small case series suggest that infliximab is beneficial for mucocutaneous lesions and (more anecdotally) for arthritis and gastro-intestinal manifestations. Two cases of neuro-Behcet treated with infliximab showed a complete resolution. Finally, in a rand…

medicine.medical_specialtyMucocutaneous zoneArthritisBehcet's diseaseDiseaseInterferon alpha-2Receptors Tumor Necrosis Factorlaw.inventionEtanerceptEtanerceptRheumatologyRandomized controlled triallawAntibodies Monoclonal; Behcet Syndrome; Chaperonin 60; Humans; Immunoglobulin G; Immunologic Factors; Interferon-alpha; Receptors Tumor Necrosis Factor; Recombinant ProteinsmedicineHumansImmunologic FactorsIFN-α2abusiness.industryBehcet SyndromeAntibodies MonoclonalInterferon-alphaChaperonin 60medicine.diseaseDermatologyeye diseasesInfliximabAdamantiades-Behçet's diseaseInfliximabRecombinant Proteinsstomatognathic diseasesImmunoglobulin GImmunologyTumour necrosis factorbusinessTolerizationUveitismedicine.drugCurrent opinion in rheumatology
researchProduct

Two consecutive clinical trials on cisplatin (CDDP), hepatic arterial infusion (HAI), and I.V. 5-fluorouracil (5-FU) chemotherapy for unresectable co…

1991

Several phase III clinical trials demonstrated that hepatic arterial chemotherapy for unresectable colorectal liver metastases is able to provide significantly higher response rates than those obtained by systemic route: in more than 500 patients collected from 6 randomized trials, the median values of objective response rates were 55% after fluoxuridine (FUdR) continuous hepatic arterial infusion (HAI) vs. 18.5% after FUdR or 5-fluorouracil (5-FU) intravenous (i.v.) chemotherapy. Furthermore, the majority of those studies reported that median survival increased in the patient subgroups treated with intrahepatic chemotherapy, even if not always statistically significant [1-6]. Certainly, FU…

medicine.medical_specialtyOrganoplatinum Compoundsmedicine.medical_treatmentPhases of clinical researchRectumGastroenterologyMetastasisHepatic arterial infusionInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansInfusions Intra-ArterialCisplatinChemotherapybusiness.industryLiver NeoplasmsGeneral MedicineMiddle Agedmedicine.diseaseSurgerySurvival RateClinical trialmedicine.anatomical_structureOncologyFluorouracilDrug EvaluationSurgeryFluorouracilColorectal NeoplasmsFloxuridinebusinessmedicine.drugJournal of Surgical Oncology
researchProduct

Orthopedic-orthodontic treatment of the patient with Turner's syndrome: Review of the literature and case report.

2018

Aims Turner syndrome (TS) patients have phenotypical variable presentations and they are more susceptible to endocrine, auto-immune, and structural anomalies. Typical clinical characteristics are short stature and premature ovarian insufficiency. Patients with TS show a typical cranial-facial morphology with bi-maxillary bi-retrusion, high-arched palate, micrognathia, and class II malocclusion. Aim of our study is to present the orthopedic-orthodontic treatment approach of a young TS patient and data of stability after 7 years. Methods and results A careful analysis of anamnestic data was performed. After extraoral and intraoral examination, cephalometric measurements and examination of mod…

medicine.medical_specialtyPalatal Expansion TechniqueCephalometryRadiographyTurner SyndromeMalocclusion Angle Class IIPremature ovarian insufficiencyShort statureoral pathology; orthodontics; rare disorders; Dentistry (all)Orthodontics CorrectiveCraniofacial Abnormalities03 medical and health sciences0302 clinical medicine030225 pediatricsOral and maxillofacial pathologyTurner syndromeMedicineHumansrare disordersChildGeneral DentistryOrthodonticsorthodonticbusiness.industryElectromyography030206 dentistrymedicine.diseaseTurner's syndromeCombined Modality TherapyOrthopedic surgeryMasticatory MusclesDentistry (all)Femalemedicine.symptomMalocclusionoral pathologyorthodonticsbusinessSpecial care in dentistry : official publication of the American Association of Hospital Dentists, the Academy of Dentistry for the Handicapped, and the American Society for Geriatric Dentistry
researchProduct

Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

2010

Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up A. Okines, M. Verheij, W. Allum, D. Cunningham & A. Cervantes On behalf of the ESMO Guidelines Working Group* GI Clinical Trials Unit, Royal Marsden Hospital, Sutton, UK; Department of Radiation Oncology and Division of Cellular Biochemistry, The Netherlands Cancer Institute—Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands; Department of Surgery, Royal Marsden Hospital, London; Department of Medicine, Royal Marsden Hospital, Sutton, UK; Department of Hematology and Medical Oncology, INCLIVA, University of Valencia, Valencia, Spain

medicine.medical_specialtyPalliative careTreatment outcomeMeta-Analysis as TopicStomach NeoplasmsAntineoplastic Combined Chemotherapy ProtocolsGastroscopyRadiation oncologyEpidemiologymedicineHumansNeoplasm MetastasisNeoplasm StagingRandomized Controlled Trials as TopicRadiotherapybusiness.industryIncidenceGeneral surgeryPalliative CareCancerHematologymedicine.diseaseCombined Modality TherapySurvival AnalysishumanitiesSurgeryEuropeClinical PracticeTreatment OutcomeOncologyClinical trials unitDiagnosis treatmentChemotherapy AdjuvantbusinessFollow-Up StudiesAnnals of Oncology
researchProduct

Detection of lymph node metastases in esophageal cancer.

2011

Lymph node status is the most important single prognostic factor in esophageal cancer. The detection of involved lymph nodes is therefore the key to cure. This article will provide a meta-analysis and metaregression analysis on the diagnostic performances of current lymph node-detection devices; discuss the recent status of the sentinel lymph node concept in esophageal cancer by the two sentinel node-mapping procedures (the radio-guided and the blue dye techniques) and the developing computed tomography (CT) lymphography; discuss the detection of micrometastases; and the potential clinical application of molecular-based patients' profiles. Combined use of endoscopic ultrasonography fine-nee…

medicine.medical_specialtyPathologyCeliac lymph nodesEsophageal NeoplasmsSentinel lymph nodeCombined useBiopsy Fine-NeedleEndosonographyBiopsymedicineHumansPharmacology (medical)Lymph nodemedicine.diagnostic_testbusiness.industrySentinel Lymph Node BiopsyMicrometastasisEsophageal cancermedicine.diseasemedicine.anatomical_structureOncologyLymphatic MetastasisRadiologyLymphLymph NodesbusinessTomography X-Ray ComputedExpert review of anticancer therapy
researchProduct

Combined 5-fluorouracil and recombinant alpha-2a-interferon vs. 5-fluorouracil alone in metastatic colorectal carcinoma: a multicenter randomized stu…

1991

medicine.medical_specialtyPathologyColorectal cancermedicine.medical_treatmentInterferon alpha-2GastroenterologyDrug Administration ScheduleMetastasisInterferonInternal medicinemedicineCarcinomaHumansChemotherapyEpitheliomabusiness.industryInterferon-alphaGeneral MedicineImmunotherapymedicine.diseaseCombined Modality TherapyRecombinant ProteinsOncologyFluorouracilColonic NeoplasmsSurgeryFluorouracilbusinessmedicine.drugJournal of surgical oncology. Supplement
researchProduct

Sequential and combined treatment of prolidase deficiency leg ulcers

2010

Background The Authors report a case of chronic cutaneous lesions in a patient affected by prolidase deficiency, a rare disorder inherited through an autosomal recessive gene (50 cases reported ). The enzyme prolidase is widely distributed throughout the body and it is important in the recycling of proline and hydroxyproline. Among the clinical presentations, the most striking manifestation is the skin fragility with leg ulceration (see Table ​Table11) Table 1 Clinical signs of prolidase deficiency The deficiency of the enzyme prolidase is responsible for massive loss of proline in the urine which is estimated to be as high as 3 g/die. The diagnosis is ascertained by iminopeptiduria greater…

medicine.medical_specialtyPathologyProlidase deficiencybusiness.industryGeriatrics gerontologyPatient affectedCutaneous lesionUrinemedicine.diseaseGastroenterologyHydroxyprolinechemistry.chemical_compoundSettore MED/18 - Chirurgia GeneraleSkin fragilityCombined treatmentchemistryInternal medicineprolidase deficiencyleg ulcerMedicineGeriatrics and GerontologyMeeting abstractbusinessplatelet gelBMC Geriatrics
researchProduct

Is there a role for recombinant tumor necrosis factor alpha in the intravesical treatment of superficial bladder tumors?--a phase II study

1995

Clinical use of recombinant tumor necrosis factor-alpha is strongly limited by its severe toxicity, mainly cardiovascular, when systemically administered. Recent studies suggest that topical (intrapleural, intraperitoneal, intratumoral) administration is free of significant toxicity. Human recombinant tumor necrosis factor-alpha was administered intravesically, at a dose of 500 mg dissolved in 30 ml of phosphate buffer (pH7.6-7.8) plus 0.25% human albumin, weekly for two months to 18 patients with papillary transitional cell carcinoma of the bladder. Of the 15 evaluable patients, four (26%) achieved a complete response. Systemic and local tolerability were excellent. Int J Urol 1995;2:100-1…

medicine.medical_specialtyPathologyUrologyUrologyPhases of clinical researchlaw.inventionlawRecurrencemedicineHumansPapillary transitional cell carcinomaCarcinoma Transitional Cellbusiness.industryTumor Necrosis Factor-alphaRecombinant ProteinRecombinant ProteinsRecombinant Tumor Necrosis Factor-AlphaIntravesical treatmentAdministration IntravesicalTolerabilityUrinary Bladder NeoplasmsToxicityRecombinant DNATumor necrosis factor alphabusinessHuman
researchProduct

Primary extranodal non-Hodgkin lymphomas of the uterus and the breast: report of three cases

1995

The authors describe one case of a rare primitive non-Hodgkin lymphoma of the uterus, and two cases of primary non-Hodgkin lymphoma of the breast. Histologically, the uterine lymphoma, although clinically confined to the uterus, was a diffuse large cell lymphoma, group G according to the Working formulation for Clinical Usage. The two cases of breast lymphoma were a centrocytic-centroblastic and a lymphoplasmocytoid non-Hodgkin lymphoma, respectively. All cases were initally treated with radical surgery plus radiotherapy, but the first patient showed an early recurrence at distant sites, which required systemic cytotoxic chemotherapy. The patient with uterine non-Hodgkin lymphoma received a…

medicine.medical_specialtyPathologyWorking Formulationmedicine.medical_treatmentMammary glandUterusBreast NeoplasmsCHOPimmune system diseaseshemic and lymphatic diseasesAntineoplastic Combined Chemotherapy ProtocolsHumansMedicineRadical surgeryChemotherapybusiness.industryLymphoma Non-HodgkinGeneral MedicineMiddle Agedmedicine.diseaseCombined Modality TherapyLymphomaRadiation therapymedicine.anatomical_structureOncologyUterine NeoplasmsFemaleSurgeryLymphoma Large B-Cell DiffuseRadiologybusinessEuropean Journal of Surgical Oncology (EJSO)
researchProduct

[Adverse reactions to human papillomavirus vaccine in the Valencian Community (2007-2011)].

2014

Introduction: In 2009, two cases of seizures in adolescents following quadrivalent human papillomavirus vaccine (qHPV) administration generated important media attention, and adversely affected public trust in this vaccine. Our objectives were to describe suspected adverse reactions (SARs) reported to the Pharmacovigilance Centre in the Valencian Community (PCVC) after administration of HPV vaccine, and to compare reporting rates of syncope and seizures following this vaccine with those of other vaccines administered to girls aged 13–15 years. Materials and methods: Descriptive study of SARs reported following administration of this vaccine to the PCVC between 2007 and 2011. Results: The cl…

medicine.medical_specialtyPediatricsHuman papillomavirusTime FactorsAdolescentVirus del papiloma humanoVaccines AdministeredHuman papillomavirus vaccinePediatricsRJ1-570Valencian communitySyncopeReporting ratePharmacovigilanceHuman Papillomavirus Recombinant Vaccine Quadrivalent Types 6 11 16 18SeizuresManagement of Technology and InnovationPharmacovigilanceMedicineHumansRetrospective StudiesbiologyVacunabusiness.industryReacción adversaSyncope (genus)PharmacovigitanceTasa de notificaciónbiology.organism_classificationSurgeryVaccinationFarmacovigilanciaSpainFemalebusinessAdverse reactionsVaccineAnales de pediatria (Barcelona, Spain : 2003)
researchProduct